Tevogen Bio Holdings Inc.

TVGN

CIK 0001860871 · Quarterly mode · latest period FY2025 (Q3) (ending 2025-09-30) · sourced from SEC EDGAR

At a glance · FY2025 (Q3)

Revenue
$0
Gross Profit
$0

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    100ROIC 277.0% (10% = solid, 20%+ = moat)
  • Liquidity
    0Current Ratio 0.22 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover -0.05x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -400.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 9190.6% · trend +71645889.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$16M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$4M
everything owned
Total liabilities
$13M
everything owed
Stockholders' equity
$-8M
shareholder claim

Recent performance · 18 quarters

Revenue↓-400.4% -$50K
$-62K
Net Income↑+2.7% +$157K
$-6M
Free Cash Flow↓-52.9% -$1M
$-3M
Operating Margin↓-39653.8pts
9190.6%

Drill down